Present and Future Therapies of Skin Diseases

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Biomedical Engineering and Biomaterials".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 3606

Special Issue Editors

Department of Dermatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
Interests: atopic dermatitis; psoriasis; chronic urticaria; hidradenitis suppurativa
Department of Dermatology, Faculty of Medicine, University of Debrecen, Egyetem tér 1., H-4032 Debrecen, Hungary
Interests: clinical and experimental dermatology; dermato-oncology; TRP-channels and skin; pruritus

Special Issue Information

Dear Colleagues,

After having come to an accurate diagnosis in a dermatology case, the first question we all face is the inevitable, “What should we use in treatment?”

Although the options are broad (e.g., topicals, phototherapy, surgery, systemic therapy), for many decades, managing cutaneous disorders has been a rigid, “dead water” area where not many changes had been seen. However, in the new millennium, especially in recent years, there have been dramatic changes in the therapeutic armamentarium. New treatments have emerged, and novel therapeutic modalities have been introduced in many areas of skin diseases, which we all must study and apply in our daily practice.

This Special Issue on “Present and Future Therapies of Skin Diseases” aims to present new and available as well as future, promising, not yet used treatments in dermatology. Articles on the management of common or less common, chronic or acute, severe or mild diseases are welcome. Topics of interest include, but are not limited to:

  • Acne, rosacea
  • Atopic dermatitis
  • Bullous skin disorders
  • Chronic urticaria
  • Hidradentis suppurativa
  • Itch/pruritus
  • Melanoma
  • Pediatric dermatology
  • Psoriasis

The issue will review and introduce to the reader the mainstream and the most dynamically progressing therapeutic areas in dermatology; however, the presentation of special treatments for vulnerable populations (e.g., elderly or pediatric dermatology, COVID-19 with cutaneous symptoms) may also be considered for publication. All papers should aim to serve and provide new information to the practicing dermatology community, offering a more profound understanding of skin disease management.

Dr. Gáspár Krisztián József
Dr. Szabó Imre Lőrinc
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory skin diseases
  • immune-mediated/autoimmune skin disorders
  • pediatric dermatology
  • skin tumors

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1776 KiB  
Article
Leveraging Genomic and Bioinformatic Analysis to Enhance Drug Repositioning for Dermatomyositis
by Lalu Muhammad Irham, Wirawan Adikusuma, Anita Silas La’ah, Rockie Chong, Abdi Wira Septama and Marissa Angelina
Bioengineering 2023, 10(8), 890; https://doi.org/10.3390/bioengineering10080890 - 27 Jul 2023
Cited by 1 | Viewed by 1189
Abstract
Dermatomyositis (DM) is an autoimmune disease that is classified as a type of idiopathic inflammatory myopathy, which affects human skin and muscles. The most common clinical symptoms of DM are muscle weakness, rash, and scaly skin. There is currently no cure for DM. [...] Read more.
Dermatomyositis (DM) is an autoimmune disease that is classified as a type of idiopathic inflammatory myopathy, which affects human skin and muscles. The most common clinical symptoms of DM are muscle weakness, rash, and scaly skin. There is currently no cure for DM. Genetic factors are known to play a pivotal role in DM progression, but few have utilized this information geared toward drug discovery for the disease. Here, we exploited genomic variation associated with DM and integrated this with genomic and bioinformatic analyses to discover new drug candidates. We first integrated genome-wide association study (GWAS) and phenome-wide association study (PheWAS) catalogs to identify disease-associated genomic variants. Biological risk genes for DM were prioritized using strict functional annotations, further identifying candidate drug targets based on druggable genes from databases. Overall, we analyzed 1239 variants associated with DM and obtained 43 drugs that overlapped with 13 target genes (JAK2, FCGR3B, CD4, CD3D, LCK, CD2, CD3E, FCGR3A, CD3G, IFNAR1, CD247, JAK1, IFNAR2). Six drugs clinically investigated for DM, as well as eight drugs under pre-clinical investigation, are candidate drugs that could be repositioned for DM. Further studies are necessary to validate potential biomarkers for novel DM therapeutics from our findings. Full article
(This article belongs to the Special Issue Present and Future Therapies of Skin Diseases)
Show Figures

Graphical abstract

5 pages, 437 KiB  
Communication
Long-Term Dose Optimization of Adalimumab via Dose Spacing in Patients with Psoriasis
by Michael Benzaquen, Mohammad Munshi, Simon Bossart, Laurence Feldmeyer, Vladimir Emelianov, Nikhil Yawalkar, Simone Cazzaniga and Kristine Heidemeyer
Bioengineering 2022, 9(8), 387; https://doi.org/10.3390/bioengineering9080387 - 13 Aug 2022
Cited by 5 | Viewed by 1641
Abstract
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness. The long-term effects of DS with adalimumab in psoriatic patients have not [...] Read more.
Dose spacing (DS) can be useful for optimizing treatment with biologics in psoriasis patients. However, interval prolongation might increase the production of anti-drug antibodies (ADA) and, therefore, reduce the drug’s effectiveness. The long-term effects of DS with adalimumab in psoriatic patients have not been reported. The goal of our study was to evaluate the long-term follow-up of psoriatic patients after adalimumab DS regarding the clinical course and determination of circulating adalimumab, TNFα levels, and anti-adalimumab antibodies. We retrospectively included seven patients treated with adalimumab for moderate-to-severe psoriasis and benefiting from DS from 2010 to 2021. The dose interval of adalimumab was extended to three weeks for all patients and then to four weeks for three of the seven patients. Adalimumab trough levels, TNFα levels, and ADA against adalimumab were measured. For six of the seven patients, absolute PASI values remained below 3 throughout the follow-up period (median = 8.0 years; range: 1.7–11.5) after DS. All the patients were satisfied with the effectiveness of their treatment regime. Within the follow-up period, an average of 63 doses of adalimumab per patient were spared. The median adalimumab trough levels were 4.7 µg/mL (range: 1.9–12.5). TNFα levels remained under 10 pg/mL (undetectable) in all except one patient. ADA against adalimumab remained negative (<10 µg/mL) during the follow-up in all patients. Our data indicate that therapeutic drug monitoring, including the measurement of trough concentrations and ADA, together with the clinical response and patient’s preference, can be helpful for clinical decision making and treatment optimization in psoriasis. Full article
(This article belongs to the Special Issue Present and Future Therapies of Skin Diseases)
Show Figures

Graphical abstract

Back to TopTop